VJOncology had the opportunity to conduct in-person interviews with these experts and obtain their perspectives on the latest progress within the field.
See our top editorial picks below, and more at VJOncology.com.
Rachael Murray YESS: integrating smoking cessation programs in lung cancer screening Rachael Murray provides an overview of the Yorkshire Enhanced Stop Smoking Study (YESS) (NCT03750110).
Sanjay Popat CALGB 140503: sub-lobar resection non-inferior to lobectomy in stage IA node-negative NSCLC Sub-lobar resection spares lung capacity which allows a potentially multimodality approach for patients who require additional treatments in the future.
Atocha Romero Pre-treatment ctDNA levels predicts OS and PFS in NADIM II In the Phase II NADIM II trial (NCT03838159), baseline ctDNA was detected in 52 of 54 pre-treatment samples and were significantly associated with tumor size.
Enriqueta Felip IMpower010: OS results of atezolizumab in resected NSCLC The study assessed atezolizumab versus best supportive care in patients with NSCLC and an OS trend in favor of atezolizumab was seen in the PD-L1 TC greater than or equal to 1% stage II-IIIA population.
Martin Reck JAVELIN Lung100, PRIMUS, NintNivo, IMpower010: investigating IO in NSCLC Martin Reck discusses results of multiple trials that assess immunotherapy in NSCLC that were presented at WCLC 2022.
Join us for the next Lung Cancer VJSession from the Video Journal of Oncology, where breast cancer experts Lizza Hendricks & Tiziana Vavalà will be reviewing the latest updates in lung cancer as presented during the World Conference on Lung Cancer (WCLC) 2022 meeting held in Vienna, Austria.
Check out our disease channels!
Check out more developments across different disease types with our dedicated disease channels, featuring expert interviews, podcasts, roundtable discussions and more
